Pfizer has been granted marketing authorization for Macugen for the treatment of neovascular (wet) age- related macular degeneration (AMD) by the European Commission. Macugen is the first treatment to target the underlying disease process and has been proven to help preserve visual acuity in patients with wet AMD. Clinical studies showed that Macugen prevented severe vision loss at twice the rate of standard care, which included photodynamic therapy.